Freestyle Digital media proudly announces the release of the workplace comedy movie LEFT AT WALL, now available to rent/own on all North American digital HD internet, cable, and satellite platforms, ...

The global pharmaceutical sterility testing market is on the brink of an extraordinary expansion, with forecasts predicting a ...

According to a recent report from Future Market Insights, the global allogeneic T-cell therapies market was valued at USD 1.1 ...

OMNY Health is partnering with Scipher Medicine. Vertex Pharmaceuticals signed a three-year deal with Orna Therapeutics to use the RNA biotech’s delivery particles to develop its next iteration of ...

Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report) and keeping the price target at $8.00. Discover outperforming stocks and invest ...

In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Rapport Therapeutics, Inc. (RAPP – Research Report). The company’s shares closed last Wednesday at $16.69.

Tenvie Therapeutics Inc. is getting a set of small-molecule drugs — specifically, ones aimed at tamping down inflammation, rescuing metabolic dysfunction and restoring lysosomal function ...

Coave Therapeutics SA has completed the transition to becoming a genetic medicines specialist, after divesting its single ophthalmology program and raising $33 million in a series A round. The new ...

Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tenvie Therapeutics launched today with a commitment to transform the treatment of neurological diseases. The company combines a deep and diverse portfolio of ...

Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing several programs—and an executive—from Denali Therapeutics.

A new company is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug candidates and raising money from one of its original investors. The biotech ...